Filing Flows › Comparisons › TOVX vs LGVN
Theriva Biologics vs Longeveron: TOVX and LGVN compared
Theriva Biologics is the larger company: $300K of revenue in its latest quarter (Q1 2026) against $287K for Longeveron (Q2 2026).
Where the money goes: TOVX and LGVN
Theriva Biologics (TOVX) · Q1 2026
Theriva Biologics, Q1 2026: revenue $300K, operating margin -709.0%, net loss $2.0M, operating cash flow −$2.5M. The chart follows the revenue to costs, profit and cash.
Longeveron (LGVN) · Q2 2026
Longeveron, Q2 2026: revenue $287K (-9% year over year), net loss $6.1M, operating cash flow −$5.7M. The chart follows the revenue to costs, profit and cash.
| Theriva Biologics (TOVX) | Longeveron (LGVN) | |
|---|---|---|
| Latest quarter | Q1 2026 | Q2 2026 |
| Revenue | $300K | $287K |
| Revenue growth, Y/Y | — | -9% |
| Operating margin | -709.0% | n/m |
| Net earnings | −$2.0M | −$6.1M |
| Net margin | -681.3% | — |
| Operating cash flow | −$2.5M | −$5.7M |
Questions
Which is bigger, Theriva Biologics or Longeveron?
Theriva Biologics is the larger company: $300K of revenue in its latest quarter (Q1 2026) against $287K for Longeveron (Q2 2026).
More: Theriva Biologics earnings · how Theriva Biologics makes money · Longeveron earnings · how Longeveron makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed May 5, 2026; 10-Q filed Aug 12, 2026). Fiscal quarters can end on different dates. Not investment advice.